OV21/PETROC: a randomized Gynecologic Cancer Intergroup phase II study of intraperitoneal versus intravenous chemotherapy following neoadjuvant chemotherapy and optimal debulking surgery in epithelial ovarian cancer. (23rd November 2017)

• Record Type: Journal Article
• Authors: Provencher, D M; Gallagher, C J; Parulekar, W R; Ledermann, J A; Armstrong, D K; Brundage, M; Gourley, C; Romero, I; Gonzalez-Martin, A; Feeney, M; Bessette, P; Hall, M; Weberpals, J I; Hall, G; Lau, S K; Gauthier, P; Fung-Kee-Fung, M; Eisenhauer, E A; Winch, C; Tu, D; MacKay, H J
• Is Part Of: Annals of oncology. Volume 29:Number 2(2018)
• Page Start: 431
• Page End: 438
• Publication Date: 2017-11-23
• Subjects: i.p. chemotherapy -- ovarian cancer -- neoadjuvant; Oncology -- Periodicals; 616.992
• DOI: 10.1093/annonc/mdx754
• Languages: English
• ISSNs: 0923-7534

Abstract

Abstract: Background: The purpose of this multistage, adaptively, designed randomized phase II study was to evaluate the role of intraperitoneal (i.p.) chemotherapy following neoadjuvant chemotherapy (NACT) and optimal debulking surgery in women with epithelial ovarian cancer (EOC). Patients and methods: We carried out a multicenter, two-stage, phase II trial. Eligible patients with stage IIB–IVA EOC treated with platinum-based intravenous (i.v.) NACT followed by optimal (<1 cm) debulking surgery were randomized to one of the three treatment arms: (i) i.v. carboplatin/paclitaxel, (ii) i.p. cisplatin plus i.v./i.p. paclitaxel, or (iii) i.p. carboplatin plus i.v./i.p. paclitaxel. The primary end point was 9-month progressive disease rate (PD9). Secondary end points included progression-free survival (PFS), overall survival (OS), toxicity, and quality of life (QOL). Results: Between 2009 and 2015, 275 patients were randomized; i.p. cisplatin containing arm did not progress beyond the first stage of the study after failing to meet the pre-set superiority rule. The final analysis compared i.v. carboplatin/paclitaxel ( n = 101) with i.p. carboplatin, i.v./i.p. paclitaxel ( n = 102). The intention to treat PD9 was lower in the i.p. carboplatin arm compared with the i.v. carboplatin arm: 24.5% (95% CI 16.2% to 32.9%) versus 38.6% (95% CI 29.1% to 48.1%) P = 0.065. The study was underpowered to detect differences in PFS: HR PFS 0.82 (95% CI 0.57–1.17); P = 0.27 and OS HR 0.80 (95% CI 0.47–1.35) P = 0.40. The i.p. carboplatin-based regimen was well tolerated with no reduction in QOL or increase in toxicity compared with i.v. administration alone. Conclusion: In women with stage IIIC or IVA EOC treated with NACT and optimal debulking surgery, i.p. carboplatin-based chemotherapy is well tolerated and associated with an improved PD9 compared with i.v. carboplatin-based chemotherapy. Clinical trial number: clinicaltrials.gov, NCT01622543.